NCT06434194

Brief Summary

TA prospective randomized control trial to evaluate the serration angioplasty effect in BTK arteries with varying degrees of calcified plaque.

Trial Health

57
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
60

participants targeted

Target at P25-P50 for not_applicable

Timeline
Completed

Started Oct 2024

Shorter than P25 for not_applicable

Geographic Reach
1 country

2 active sites

Status
recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

May 3, 2024

Completed
27 days until next milestone

First Posted

Study publicly available on registry

May 30, 2024

Completed
5 months until next milestone

Study Start

First participant enrolled

October 31, 2024

Completed
7 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

June 1, 2025

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

June 1, 2025

Completed
Last Updated

May 18, 2025

Status Verified

May 1, 2025

Enrollment Period

7 months

First QC Date

May 3, 2024

Last Update Submit

May 14, 2025

Conditions

Outcome Measures

Primary Outcomes (1)

  • Residual Lumen Volume Stenosis

    Residual lumen volume stenosis derived by OCT comparing Serration Angioplasty and conventional plain balloon angioplasty (PTA) measured at 10-15min post procedure. The lesion segment is defined as the entire treated segment where the balloon has been inflated.

    Baseline

Secondary Outcomes (6)

  • OCT Residual Diameter Stenosis

    Baseline

  • Angiography Residual Diameter Stenosis

    Baseline

  • Dissection Pattern

    Baseline

  • Correlation of Luminal Gain and Plaque Modification

    Baseline

  • Rate of Optimal PTA

    Baseline

  • +1 more secondary outcomes

Study Arms (2)

Serrantor

ACTIVE COMPARATOR

Subjects randomized to the Serranator Arm of the study will be treated with the Serranator PTA Serration Balloon

Device: Serranator PTA Serration Catheter

PTA

ACTIVE COMPARATOR

Subjects randomized to the PTA Arm of the study will be treated with a standard of care percutaneous transluminal angioplasty (PTA) balloon.

Drug: PTA (Standard of Care)

Interventions

The Serranator PTA Serration Balloon Catheter is an over-the-wire balloon dilatation catheter designed to perform percutaneous transluminal angioplasty (PTA) for peripheral indications.

Serrantor

A percutaneous transluminal angioplasty catheter will be used to treat the target lesion.

PTA

Eligibility Criteria

Age19 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Rutherford clinical category 4-6 of the target limb
  • Age of subjects is \>18 years old
  • Patients has given informed consent to participate in this study

You may not qualify if:

  • De novo or restenotic (without prior stent) stenosis (≥70%) or occlusion
  • Target lesion is in the BTK arteries, including below the knee popliteal, tibioperoneal trunk, tibial, peroneal, and pedal arteries.
  • Angiographic visual estimated reference vessel diameter is between 2.0 and 5.0 mm.
  • Lesion length less than 220 mm

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (2)

Columbia University

New York, New York, 10032, United States

RECRUITING

Weill Cornell Medical

New York, New York, 10065, United States

RECRUITING

MeSH Terms

Conditions

Chronic Limb-Threatening Ischemia

Interventions

Standard of Care

Condition Hierarchy (Ancestors)

Peripheral Arterial DiseaseAtherosclerosisArteriosclerosisArterial Occlusive DiseasesVascular DiseasesCardiovascular DiseasesPeripheral Vascular DiseasesChronic DiseaseDisease AttributesPathologic ProcessesPathological Conditions, Signs and SymptomsIschemia

Intervention Hierarchy (Ancestors)

Quality Indicators, Health CareQuality of Health CareHealth Services AdministrationHealth Care Quality, Access, and Evaluation

Central Study Contacts

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
TRIPLE
Who Masked
PARTICIPANT, CARE PROVIDER, OUTCOMES ASSESSOR
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
INDUSTRY
Responsible Party
SPONSOR

Study Record Dates

First Submitted

May 3, 2024

First Posted

May 30, 2024

Study Start

October 31, 2024

Primary Completion

June 1, 2025

Study Completion

June 1, 2025

Last Updated

May 18, 2025

Record last verified: 2025-05

Data Sharing

IPD Sharing
Will not share

Locations